Literature DB >> 8610366

Administration of rabbit anti-asialo GM1 antiserum facilitates the development of human Epstein-Barr virus-induced lymphoproliferations in xenografted C.B-17 scid/scid mice.

J F Lacerda1, M Ladanyi, C Jagiello, R J O'Reilly.   

Abstract

Mice with severe combined immune deficiency (C.B-17 scid/scid [SCID mice]) lack functional B and T lymphocytes and are permissive for the growth of human xenografts. However, the development of functional NK cells is not affected by the scid mutation. Mouse NK cells express the surface glycolipid asialo GM1 and are implicated in the rejection of heterotransplanted cells. In the present study, we demonstrate that SCID mice treated with rabbit anti-asialo GM anti-serum (alpha-asialo GM1), for in vivo depletion of endogenous NK cell function, develop lethal Epstein-Barr virus (EBV)-induced lymphoproliferative disorders (EBV-LPD) at lower doses od inoculated EBV-transformed lymphoblastoid B cell lines (EBV-LCL) than untreated animals. Furthermore, at any given dose of EBV-LCL inoculated, EBV-LPD developed earlier and induced lethality sooner in alpha-asialo GM1-treated animals. We also demonstrate that SCID mice treated with alpha-asialo GM1 have reduction in the number of asialo GM1-expressing splenocytes. Moreover, splenic cell suspensions derived from alpha-asialo GM1-treated SCID mice show lower cytotoxicity against the mouse NK-sensitive cell line YAC-1 and human EBV-LCL than splenocytes obtained from untreated SCID mice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8610366     DOI: 10.1097/00007890-199602150-00030

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

Review 1.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

2.  The mother lode of liver transplantation, with particular reference to our new journal.

Authors:  T E Starzl
Journal:  Liver Transpl Surg       Date:  1998-01

3.  Fine-tuning the EBV+ hu-PBL-SCID xenogeneic chimera model using in vivo superinfection.

Authors:  K Kvell ; P Balogh ; P Németh
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

4.  Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease.

Authors:  Erin Hertlein; Kyle A Beckwith; Gerard Lozanski; Timothy L Chen; William H Towns; Amy J Johnson; Amy Lehman; Amy S Ruppert; Brad Bolon; Leslie Andritsos; Arletta Lozanski; Laura Rassenti; Weiqiang Zhao; Tiina M Jarvinen; Leigha Senter; Carlo M Croce; David E Symer; Albert de la Chapelle; Nyla A Heerema; John C Byrd
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.